The Best Dividend King to Buy With $150
Shares of Abbott Laboratories (NYSE: ABT) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away from Abbott given some recent challenges. However, Abbott's stock still remains attractive, especially for dividend-seeking investors. Here is why.
Abbott Laboratories' fourth-quarter top-line growth came up short of expectations. The company's sales were $11.5 billion, up 4.4% compared to the year-ago period. Two of the company's business segments, nutrition and diagnostics, moved in the wrong direction. And to make matters worse, the company's guidance for its fiscal 2026 was not strong either. It's not that surprising, then, that Abbott's shares fell sharply on the heels of its earnings release.
Image source: Getty Images.
Source Fool.com
Abbott Laboratories Aktie
Überwältigendes Buy-Interesse für Abbott Laboratories: 47 Buy-Einschätzungen ohne eine einzige Sell-Einschätzung.
Eine Steigerung von über 20% ist für Abbott Laboratories möglich, angesichts eines Kursziels von 124 € gegenüber 93.22 €.
